Clinical Trial Update: A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) [Phase 3]

View source ↗

Summary

Phase 3 trial of subcutaneously administered Bremelanotide in premenopausal women with Hypoactive Sexual Desire Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoactive Sexual Desire Disorder

Drugs mentioned

• Bremelanotide (bremelanotide)

Snippet

Sponsor: Kwang Dong Pharmaceutical co., ltd. | Conditions: Hypoactive Sexual Desire Disorder | Phase 3 | Status: COMPLETED